

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



August 14, 2023

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.  
**NSE Code: SUNPHARMA**

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.  
**Stock Code: 524715**

Dear Sir/Madam,

**Sub: Disclosure (details of litigation) under regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

Pursuant to aforesaid Regulations, we hereby intimate the details regarding the litigations of the Company / its subsidiaries. Further, the details as required under the SEBI circular dated July 13, 2023 are provided in **Annexure-A** enclosed herewith.

This is for your information and record.

Thanking you,

Yours faithfully,  
**For Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



### Annexure-A

#### **Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

(Rs. In Crore)

<b>Sr. No.</b>	<b>Name(s) of opposing Party</b>	<b>Court / tribunal agency where the litigation is filed</b>	<b>Brief details of dispute / litigation</b>	<b>Expected financial implications, if any, due to compensation, penalty etc.;</b>	<b>Quantum of claims, if any;</b>
1	DCIT - Circle 2(1)(1) - Baroda	ITAT - Ahmedabad	Adjustment to Income made during assessment under section 143(3) of the Income-tax Act	The aggregate amount of litigation is Rs. 400.40 crore which is pertaining to assessment year 2014-15. The company has disclosed this amount as contingent liability in its Annual Report	400.40
2	DCIT - Circle 2(1)(1) - Baroda	ITAT - Ahmedabad	Adjustment to Income made during assessment under section 143(3) of the Income-tax Act	The aggregate amount of litigation is Rs. 263.78 crore which is pertaining to assessment year 2015-16. The company has disclosed this amount as contingent liability in its Annual Report	263.78
3	DCIT - Circle 2(1)(1) - Baroda	Gujarat High Court	Penalty on adjustment to Income made during assessment under section 143(3) of the Income-tax Act	The aggregate amount of litigation towards penalty is Rs. 521.45 crore which is pertaining to assessment year 2015-16. The company has disclosed this amount as contingent liability in its Annual Report	521.45
4	DCIT - Circle 2(1)(1) - Baroda	CIT(A) NFAC, Delhi & CIT(A)-13, Ahmedabad	Adjustment to Income made during assessment under section 143(3) of the Income-tax Act	The aggregate amount of litigation is Rs. 506.07 crore which is pertaining to assessment year 2016-17. The company has disclosed this amount as contingent liability in its Annual Report	506.07
5	DCIT - Circle 2(1)(1) - Baroda	CIT(A) NFAC, Delhi & CIT(A)-13, Ahmedabad	Adjustment to Income made during assessment under section 143(3) of the Income-tax Act	The aggregate amount of litigation is Rs. 487.40 crore which is pertaining to assessment year 2017-18. The company has disclosed this amount as contingent liability in its Annual Report	487.40

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



Sr. No.	Name(s) of opposing Party	Court / tribunal agency where the litigation is filed	Brief details of dispute / litigation	Expected financial implications, if any, due to compensation, penalty etc.;	Quantum of claims, if any;
6	DCIT - Circle 2(1)(1) - Baroda	CIT(A) NFAC, Delhi & CIT(A)-13, Ahmedabad	Adjustment to Income made during assessment under section 143(3) of the Income-tax Act	The aggregate amount of litigation is Rs. 410.56 crore which is pertaining to assessment year 2019-20. The company has disclosed this amount as contingent liability in its Annual Report	410.56
7	Commissioner - Service Tax, Mumbai	CESTAT- Mumbai	Service tax on Out of Court Settlement Expenses	The aggregate amount of litigation is Rs. 355.0 crore which is pertaining to Patent infringement (Pfizer) for the period 2013-14. The company has not considered this amount as contingent liability in its Annual Report	355.00

**Note on Legal Proceedings** – The Company and/or its subsidiaries are involved in various legal proceedings (details of which are provided at Note No. 39 of the consolidated financial statements), including but not limited to product liability claims, contract disputes, employment claims, antitrust matters, compliance matters, and other legal and regulatory matters relating to the conduct of its business. Some of the key matters are discussed below. Most of the legal proceedings involve complex issues, which are specific to the case and do not have precedents, and, hence, for a majority of these claims, it is not possible to make a reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings. This is due to a number of factors, including: the stage of the proceedings and the overall length of the discovery process; the entitlement of the parties to an action to appeal a decision; the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate; the possible need for further legal proceedings to establish the appropriate amount of damages, if any; the settlement posture of the other parties to the litigation; and any other factors that may have a material effect on the litigation. The Company makes its assessment of likely outcomes based on the views of internal legal counsel and in consultation with external legal counsel representing the Company. The Company also believes that disclosure of the amount sought by plaintiffs would not be meaningful because historical evidence indicates that the amounts settled (if any) are significantly different than those claimed by plaintiffs. Some of the legal claims against the Company, if decided against the Company or settled by the Company, may result in significant impact on its consolidated financial statements.